



Avalanche Biotechnologies to Present at Upcoming Scientific Meetings

April 28, 2015

MENLO PARK, Calif., April 28, 2015 (GLOBE NEWSWIRE) -- Avalanche Biotechnologies, Inc. (Nasdaq:AAVL), a clinical-stage biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need, announced today that in May, it and certain of its research partners will present at the Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting in Denver, as well as at the American Society of Gene & Cell Therapy (ASGCT) 18th Annual Meeting in New Orleans.

ARVO 2015 Annual Meeting

May 3-7, Denver

Oral Presentation:

One-Year Analysis of sFlt-1 and VEGF Proteins and Immunological Markers in the Bodily Fluids of Subjects Participating in the Phase I rAAV.sFlt-1 Trial

Presenter: Elizabeth (Piroska) Rakoczy, PhD, The University of Western Australia

Date/Time: Monday, May 4, 8:45 a.m. – 9:00 a.m. MT

Poster Presentations:

Neuroprotective Effect of AAV-Mediated Cell-Specific Expression of GDNF in Müller Glial Cells Versus Retinal Ganglion Cells in a Murine Model of Glaucoma

Presenter: Chendong Pan, PhD, Weill Cornell Medical College

Date/Time: Monday, May 4, 3:45 p.m. – 5:30 p.m. MT

Association of Geographic Atrophy (GA) and Visual Acuity (VA) with Anti-VEGF Therapy Exposure in the Comparison of Age-Related Macular Degeneration Treatments Trial (CATT)

Presenter: Szilárd Kiss, MD, Weill Cornell Medical College

Date/Time: Tuesday, May 5, 8:30 a.m. – 10:15 a.m. MT

About Avalanche Biotechnologies, Inc.

Avalanche is a biopharmaceutical company committed to improving or preserving the sight of people suffering from blinding eye diseases with an unmet medical need. Avalanche's proprietary Ocular BioFactory™ is a platform for discovering and developing novel medicines with the potential to offer life-changing therapeutic benefit. Avalanche's lead product candidate, AVA-101, is in mid-stage clinical development for patients with wet age-related macular degeneration. For more information, please visit www.avalanchebiotech.com.

CONTACT: Investor Contact

Lauren Glaser
(650) 656-9347

lauren@avalanchebiotech.com

Media Contact

Carolyn Wang
(415) 946-1065

cwang@w2ogroup.com

[Avalanche Biotechnologies Logo](#)

Avalanche Biotechnologies, Inc.